# 900276009 12/31/2013

# TRADEMARK ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: SECURITY INTEREST

#### **CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
CymaBay Therapeutics, Inc.	FORMERLY Metabolex, Inc.	09/30/2013	CORPORATION: DELAWARE

## **RECEIVING PARTY DATA**

Name:	Silicon Valley Bank
Street Address:	3003 Tasman Drive
City:	Santa Clara
State/Country:	CALIFORNIA
Postal Code:	95054
Entity Type:	CORPORATION: CALIFORNIA

Name:	Oxford Finance LLC
Street Address:	133 North Fairfax Street
City:	Alexandria
State/Country:	VIRGINIA
Postal Code:	22314
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE

# PROPERTY NUMBERS Total: 3

Property Type	Number	Word Mark
Serial Number:	85954299	СҮМАВАҮ
Serial Number:	85954291	СҮМАВАҮ
Serial Number:	74604849	METABOLEX

## **CORRESPONDENCE DATA**

**Fax Number**: 8586385130

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

via US Mail.

Phone: 858-677-1400

Email: susan.reynholds@dlapiper.com

TRADEMARK REEL: 005184 FRAME: 0172 85954299

CH \$90.00

900276009

Correspondent Name: DLA Piper LLP (US) Address Line 1: 4365 Executive Drive, Suite 1100 Address Line 4: San Diego, CALIFORNIA 92121 ATTORNEY DOCKET NUMBER: 354271-509 NAME OF SUBMITTER: Troy Zander Signature: /s/ Troy Zander Date: 12/31/2013 Total Attachments: 51 source=IPSA#page1.tif source=IPSA#page2.tif source=IPSA#page3.tif source=IPSA#page4.tif source=IPSA#page5.tif source=IPSA#page6.tif source=IPSA#page7.tif source=IPSA#page8.tif source=IPSA#page9.tif source=IPSA#page10.tif source=IPSA#page11.tif source=IPSA#page12.tif source=IPSA#page13.tif source=IPSA#page14.tif source=IPSA#page15.tif source=IPSA#page16.tif source=IPSA#page17.tif source=IPSA#page18.tif source=IPSA#page19.tif source=IPSA#page20.tif source=IPSA#page21.tif source=IPSA#page22.tif source=IPSA#page23.tif source=IPSA#page24.tif source=IPSA#page25.tif source=IPSA#page26.tif source=IPSA#page27.tif source=IPSA#page28.tif source=IPSA#page29.tif source=IPSA#page30.tif

source=IPSA#page31.tif source=IPSA#page32.tif source=IPSA#page33.tif source=IPSA#page34.tif source=IPSA#page35.tif source=IPSA#page36.tif source=IPSA#page37.tif source=IPSA#page38.tif source=IPSA#page39.tif source=IPSA#page40.tif source=IPSA#page41.tif

TRADEMARK

REEL: 005184 FRAME: 0173

		ı
source=IPSA#page42.tif		
source=IPSA#page43.tif		
source=IPSA#page44.tif		
source=IPSA#page45.tif		
source=IPSA#page46.tif		
source=IPSA#page47.tif		
source=IPSA#page48.tif		
source=IPSA#page49.tif		
source=IPSA#page50.tif		
source=IPSA#page51.tif		
		$\Box$

#### INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement ("Agreement") is entered into as of September 30, 2013 by and among SILICON VALLEY BANK ("Bank"), OXFORD FINANCE LLC ("Oxford") and CYMABAY THERAPEUTICS, INC. ("Grantor").

## **RECITALS**

- A. Bank and Oxford have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "Loans") in the amounts and manner set forth in that certain Loan and Security Agreement by and among Bank, Oxford and Grantor dated as of September 30, 2013 (as the same may be amended, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). Bank and Oxford are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Bank and Oxford a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor under the Loan Agreement.
- B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Bank and Oxford a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.
- NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

# **AGREEMENT**

- 1. <u>Grant of Security Interest</u>. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Bank and Oxford a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:
- (a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on <a href="Exhibit A">Exhibit A</a> attached hereto (collectively, the "Copyrights");
- (b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;
- (c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;
- (d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on <u>Exhibit B</u> attached hereto (collectively, the "Patents");

WEST\242273251.5 354271-000509

- (e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on <u>Exhibit</u> C attached hereto (collectively, the "Trademarks");
- (f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the "Mask Works");
- (g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;
- (h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;
- (i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and
- (j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.
- 2. <u>Recordation</u>. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Bank.
- 3. <u>Authorization</u>. Grantor hereby authorizes Bank to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement, and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.
- 4. <u>Loan Documents.</u> This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Bank and Oxford with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.
- 5. <u>Execution in Counterparts.</u> This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart of this Agreement.
- 6. <u>Successors and Assigns</u>. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.
- 7. <u>Governing Law.</u> This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the

laws of the United States and the State of California, without giving effect to any choice or conflict of law provision or rule (whether of the State of California or any other jurisdiction).

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:
CYMABAY THERAPEUTICS, INC.
By: HAROLD VAN WART Title: PRESIDENT & CEA
BANK:
SILICON VALLEY BANK
By:Title:
OXFORD:
OXFORD FINANCE LLC
Ву:

[Signature Page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:
CYMABAY THERAPEUTICS, INC.
Ву:
Title:
BANK;
SILICON VALLEY BANK
Quel + 614-
By: Tennife/Friel Goldstein Title: Monaging Diveotor
OXFORD:
OXFORD FINANCE LLC
Ву:
Title:

[Signature Page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRAN	FOR:
СҮМА	BAY THERAPEUTICS, INC.
By:	
Title:	
BANK:	\$
SILICO	ON VALLEY BANK
By:	
OXFOI	RD:
OXFO	RD FINANCE LLC
	Ma)
By:	Vice President - Finance, Secretary & Treasure

[Signature Page to Intellectual Property Security Agreement]

# EXHIBIT A

Copyrights

Registration/ Application Number Registration/ Application <u>Date</u> **Description** 

None registered.

# EXHIBIT B

# Patents

		Status, Filing Date,	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: USE OF (-) (3-TRI HALOMETHYLPHENOXY)	Austria	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # E336235
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	
Title: USE OF (-) (3-TRI HALOMETHYLPHENOXY)	Belgium	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR	_	Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	
Title: Use of (-)(3-Trihalomethylphenoxy)	Canada	Status: Issued	Expires: 6/2/2020
(4-Halophenyl) Acetic Acid Derivatives for Treatment of		Filed: 6/2/2000	
Insulin Resistance, Type 2 Diabetes, Hyperlipidemia and		Serial #: 2371723	
Hyperuricemia		Conf #: None	
Title: USE OF (-) (3-TRI HALOM ETHYL PH ENOXY)	Switzerland	Status: Issued	Issued: 8/16/2006
4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	
Title: USE OF (-) (3-TRI HALOM ETHYL PH ENOXY) (4-	Chile	Status: Issued	Expires: 6/2/2020
HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	
TREATMENT OF INSULIN RESISTANCE,		Serial #: 1444-2000	
		Conf #: None	
Title: USE OF (-) (3-	China	Status: Issued	Issued: 2/16/2005
TRI HALOM ETHYL PH ENOXY)		Filed: 6/2/2000	Pat. # ZL00811290.8
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Serial #: 811290.8	Expires: 6/2/2020
TREATMENT OF INSULIN RESISTANCE,		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-	Cyprus	Status: Issued	Issued: 8/16/2006
HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	

WEST\242273251.5 354271-000509

		Status, Filing Date,	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Germany	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 60030109.5
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Denmark	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	EPO	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Spain	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR	•	Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Finland	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	France	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	United Kingdom	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	

		Status, Filing Date,	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Greece	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Hungary	Status: Pending	Expires: 6/2/2020
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	
TREATMENT OF INSULIN RESISTANCE,		Serial #: P0201611	
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Ireland	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	India	Status: Pending	Expires: 6/2/2020
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	
TREATMENT OF INSULIN RESISTANCE,		Serial #: 2001/01320	
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Italy	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Japan	Status: Issued	Issued: 2/18/2011
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 4685300
TREATMENT OF INSULIN RESISTANCE,		Serial 2001-501203	Expires: 6/2/2020
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Luxembourg	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	-

Title	Country	Status, Filing Date, App. Serial No.	Pat/Reg No., Issue/Reg Date
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Monaco	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR	Monaco	Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
TRESTINENT OF INSCERN RESISTANCE,		Conf #: None	Expires: 6/2/2020
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Netherlands	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR	Tienerianas	Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
TREATMENT OF INSOLITANCE,		Conf #: None	Парнов. 6/2/2020
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Philippines	Status: Issued	Issued: 11/9/2007
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR	1 milppines	Filed: 6/2/2000	Pat. # 1-2000-001455
TREATMENT OF INSULIN RESISTANCE, TYPE 2		Serial #: 1-2000-01455	Expires: 6/2/2020
DIABETES AND HYPERLIPIDEMIA		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Portugal	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Sweden	Status: Issued	Issued: 8/16/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 1183020
TREATMENT OF INSULIN RESISTANCE,		Serial #: 938074.2	Expires: 6/2/2020
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Taiwan	Status: Issued	Issued: 10/21/2006
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/3/2000	Pat. # 1264303
TREATMENT OF INSULIN RESISTANCE,		Serial #: 89110927	Expires: 6/2/2020
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Ukraine	Status: Issued	Issued: 11/15/2005
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. # 74147
TREATMENT OF INSULIN RESISTANCE, TYPE 2		Serial #: 2001129087	Expires: 6/2/2020
DIABETES AND PHARMACEUTICAL COMPOSITIONS		Conf #: None	
Title: USE OF (-) (3- TRIHALOMETHYLPHENOXY)	US	Status: Issued	Issued: 7/17/2001
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/4/1999	Pat. # 6262118
TREATMENT OF INSULIN RESISTANCE,		Serial #: 09/325,997	
		Conf #: None	

Title	Comba	Status, Filing Date,	Pat/Reg No.,
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE	Country Venezuela	App. Serial No.  Status: Pending Filed: 6/5/2000 Serial #: 1230-2000 Conf #: None	Expires: 6/2/2020
Title: Use of (-)-(3-Trihalomethylphenoxy)(4-Halophenyl) Acetic Acid Derivatives for Treatment of Hyperuricaemia	Austria	Status: Issued Filed: 6/2/2000 Serial #: None Conf #: None	Issued: 9/14/2011 Pat. # 1614418
Title: Use of (-)(3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Hyperuricaemia	Belgium	Status: Issued Filed: 6/2/2000 Serial #: None Conf #: None	Issued: 9/14/2011 Pat. # 1614418
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICAEMIA	Canada	Status: Pending Filed: 6/2/2000 Serial #: 2751187 Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE,	Switzerland	Status: Issued Filed: 6/2/2000 Serial #: 50769017 Conf #: None	Issued: 9/14/2011 Pat. #: 1614418
Title: USE OF (-)(3-TRIHALOMETHYLPHENOXY)(4 -HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES AND HYPERLIPIDEMIA	Chile	Status: Abandoned Filed: 6/2/2000 Serial #: 1971-2011 Conf #: None	Abandoned:
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE,	China	Status: Issued Filed: 6/2/2000 Serial #: 2.00E+11 Conf #: None	Issued: 4/9/2008 Pat. #: ZL200410011657.4
Title: Use of (-)(3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Hyperuricaemia	Cyprus	Status: Issued Filed: 6/2/2000 Serial #: CY1112861 Conf #: None	Issued: 9/14/2011 Pat. #: 1614418 Expires: 6/2/2020

Title	Country	Status, Filing Date, App. Serial No.	Pat/Reg No., Issue/Reg Date
Title: Use of (-)(3-Trihalomethylphenoxy) (4-Halophenyl)	Germany	Status: Issued	Issued: 9/14/2011
Acetic Acid Derivatives for Treatment of Hyperuricaemia	Germany	Filed: 6/2/2000	Pat. #: 1614418
rectic retarbetivatives for Treatment of Hyperanicaenna		Serial #: None	1 40. 77. 1017710
		Conf #: None	
Title: Use of (-)(3-Trihalomethylphenoxy) (4-Halophenyl)	Denmark	Status: Issued	Issued: 9/14/2011
Acetic Acid Derivatives for Treatment of Hyperuricaemia		Filed: 6/2/2000	Pat. #: 1614418
		Serial #: None	1
		Conf #: None	
Title: Use of (-)-(3-trihalomethylphenoxy) (4-	EPO	Status: Issued	Issued: 9/14/2011
halophenyl)acetic acid derivatives for treatment of		Filed: 6/2/2000	Pat. #: 1614418
hyperuricaemia		Serial #: 05076901.7	
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Spain	Status: Issued	Issued: 9/14/2011
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. #: 1614418
TREATMENT OF INSULIN RESISTANCE,		Serial #: 50769017	
		Conf #: None	
Title: Use of (-)-(3-Trihalomethylphenoxy) (4-Halophenyl)	Finland	Status: Issued	Issued: 9/14/2011
Acetic Acid Derivatives for Treatment of Hyperuricaemia		Filed: 6/2/2000	Pat. #: 1614418
		Serial #: None	
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	France	Status: Issued	Issued: 9/14/2011
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. #: 1614418
TREATMENT OF INSULIN RESISTANCE,		Serial #: None	
		Conf #: None	
Title: USE OF (-) (3- TRIHALOMETHYLPHENOXY)	United Kingdom	Status: Issued	Issued: 9/14/2011
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. #: 1614418
TREATMENT OF INSULIN RESISTANCE,		Serial #: 50769017	
		Conf #: None	
Title: Use of (-)-(3-Trihalomethylphenoxy) (4-Halophenyl)	Greece	Status: Issued	Issued: 9/14/2011
Acetic Acid Derivatives for Treatment of Hyperuricaemia		Filed: 6/2/2000	Pat. #: 1614418
		Serial #: None	
		Conf #: None	

Title	Country	Status, Filing Date, App. Serial No.	Pat/Reg No., Issue/Reg Date
Title: Use of (-)(3-Trihalophenoxy) (4-Halophenyl)acetic Acid Derivatives for Treatment of Hyperuricaemia	Hong Kong	Status: Pending Filed: 6/2/2000 Serial #: 06107787.6 Conf #: None	issuericg paic
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE,	Hungary	Status: Issued Filed: 6/2/2000 Serial #: P1100450 Conf #: None	Issued: 9/14/2011 Pat. #: 1614418
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA	Indonesia	Status: Issued Filed: 6/2/2000 Serial #: W-00200401651 Conf #: None	Issued: 6/27/2006 Pat. #: ID0017682
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE,	Ireland	Status: Issued Filed: 6/2/2000 Serial #: 50769017 Conf #: None	Issued: 9/14/2011 Pat. #: 1614418
Title: Pharmaceutical Compositions Containing (-)(3- Trihalomethylphenoxy)(4-Halophenyl) Acetic Acid Derivatives	Israel	Status: Issued Filed: No Date Serial #: 187605 Conf #: None	Issued: 11/1/2012 Pat. #: 187605 Expires: 6/2/2020
Title: Use of (-)(3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Hyperuricaemia	Italy	Status: Issued Filed: 6/2/2000 Serial #: None Conf #: None	Issued: 9/14/2011 Pat. #: 1614418
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE,	Japan	Status: Issued Filed: 6/2/2000 Serial #: 2007-13175 Conf #: None	Issued: 2/18/2011 Pat. #: 4685808
Title: Use of (-)(3-Trihalomethylphenoxy) (4-Halophenyl)Acetic Acid Derivatives for Treatment of Insulin Resistance, Type 2 Diabetes, Hyperlipidemia and Hyperuricemia	South Korea	Status: Pending Filed: No Date Serial #: 10-0779787 Conf #: None	

TTO	C	Status, Filing Date.	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Luxembourg	Status: Issued	Issued: 9/14/2011
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. #: 1614418
TREATMENT OF INSULIN RESISTANCE,		Serial #: 50769017 Conf #: None	
Tide HECOE ( ) (2 TOHIAL OMETHYL DHENOVY)	Monaco	Status: Issued	Issued: 9/14/2011
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR	IVIOHACO	Filed: 6/2/2000	Pat. #: 1614418
/		Serial #: 50769017	rat. #: 101 <del>44</del> 16
TREATMENT OF INSULIN RESISTANCE,		Conf #: None	
Televities OE ( ) (2 TDHIAL OMETHYL DHENOVY)	Mexico	Status: Issued	Issued: 4/9/2008
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Wexico	·	
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000	Pat. #: 256188
TREATMENT OF INSULIN RESISTANCE,		Serial #: PA/a/2005/012736	
Televities OF ( ) (2 TRIBLAL OMETHINI DIJENIOVA)	Netherlands	Conf #: None Status: Issued	January 0/14/2011
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Netherlands		Issued: 9/14/2011
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 6/2/2000 Serial #: 50769017	Pat. #: 1614418
TREATMENT OF INSULIN RESISTANCE,		Conf #: None	
Tide USE OF ( ) (2 TRILLAL OMETHYL DUENOVY)	Doutugal	Status: Issued	Issued: 9/14/2011
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR	Portugal	Filed: 6/2/2000	Pat. #: 1614418
TREATMENT OF INSULIN RESISTANCE,		Serial #: 50769017	rat. #. 101 <del>44</del> 10
TREATMENT OF INSULIN RESISTANCE,		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	Sweden	Status: Issued	Issued: 9/14/2011
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR	Sweden	Filed: 6/2/2000	Pat. #: 1614418
TREATMENT OF INSULIN RESISTANCE,		Serial #: 50769017	rat. #. 101 <del>44</del> 10
TREATMENT OF INSULIN RESISTANCE,		Conf #: None	
Title: LISE OF ( ) (2 TDIUAL OMETUVI DUENOVV)	Indonesia	Status: Issued	Issued: 2/4/2008
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR	muonesia	Filed: 6/2/2000	Pat. #: ID0020456
TREATMENT OF INSULIN RESISTANCE, TYPE 2		Serial #: W-00200601542	11 at. #. 1D0020430
DIABETES AND HYPERLIPIDERMIA		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	US	Status: Issued	Issued: 9/2/2003
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR	US	Filed: 6/2/2000	Pat. #: 6613802
TREATMENT OF INSULIN RESISTANCE, TYPE 2		Serial #: 09/585.907	Expires: 6/4/2019
· ·		Conf #: None	Lapites, 0/4/2019
DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA		Colli #. Nolic	

Title	Country	Status, Filing Date, App. Serial No.	Pat/Reg No., Issue/Reg Date
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	US	Status: Issued	Issued: 11/11/2003
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 10/31/2000	Pat. #: 6646004
TREATMENT OF INSULIN RESISTANCE, TYPE 2		Serial #: 09/703,487	Expires: 6/4/2019
DIABETES AND HYPERLIPIDEMIA		Conf #: None	
Title: Use of (-)(3-Trihalomethylphenoxy) (4-Halophenyl)	US	Status: Issued	Issued: 1/15/2013
Acetic Acid Derivatives for Treatment of Insulin Resistance,		Filed: 7/16/2009	Pat. #: 8354448
Type 2 Diabetes and Hyperlipidemia		Serial #: 12/504,487	
		Conf #: None	
Title: Use of (-)-(3-Halomethylphenoxy) (4-Halophenyl)	Switzerland and	Status: Issued	Issued: 10/31/2012
Acetic Acid Derivatives for Treatment of Insulin Resistance	Liechtens	Filed: No Date	Pat. #: 1343493
Type 2 Diabetes, Hyperlipidemia and Hyperuricemia		Serial #: 01987124.3	Expires: 11/28/2021
		Conf #: None	
Title: Use of (-)-(3-Halomethylphenoxy) (4-Halophenyl)	Germany	Status: Issued	Issued: 10/31/2012
Acetic Acid Derivatives for Treatment of Insulin Resistance		Filed: No Date	Pat. #: 1343493
Type 2 Diabetes, Hyperlipidemia and Hyperuricemia		Serial #: 01987124.3	Expires: 11/28/2021
		Conf #: None	
Title: Use of (-)-(3-Halomethylphenoxy) (4-Halophenyl)	EPO	Status: Issued	Issued: 10/31/2012
Acetic Acid Derivatives for Treatment of Insulin Resistance		Filed: 11/28/2001	Pat. #: 1343493
Type 2 Diabetes, Hyperlipidemia and Hyperuricemia		Serial #: 01987124.3	
		Conf #: None	
Title: Use of (-)-(3-Halomethylphenoxy) (4-Halophenyl)	Spain	Status: Issued	Issued: 10/31/2012
Acetic Acid Derivatives for Treatment of Insulin Resistance		Filed: No Date	Pat. #: 1343493
Type 2 Diabetes, Hyperlipidemia and Hyperuricemia		Serial #: 01987124.3	Expires: 11/28/2021
		Conf #: None	
Title: Use of (-)-(3-Halomethylphenoxy) (4-Halophenyl)	France	Status: Issued	Issued: 10/31/2012
Acetic Acid Derivatives for Treatment of Insulin Resistance		Filed: No Date	Pat. #: 1343493
Type 2 Diabetes, Hyperlipidemia and Hyperuricemia		Serial #: 01987124.3	Expires: 11/28/2021
		Conf #: None	
Title: Use of (-)-(3-Halomethylphenoxy) (4-Halophenyl)	United Kingdom	Status: Issued	Issued: 10/31/2012
Acetic Acid Derivatives for Treatment of Insulin Resistance		Filed: No Date	Pat. #: 1343493
Type 2 Diabetes, Hyperlipidemia and Hyperuricemia		Serial #: 01987124.3	Expires: 11/28/2021
		Conf #: None	

Title	Country	Status, Filing Date, App. Serial No.	Pat/Reg No., Issue/Reg Date
Title: Use of (-)-(3-Halomethylphenoxy)(4-Halophenyl)	Ireland	Status: Issued	Issued: 10/31/2012
Acetic Acid Derivatives for Treatment of Insulin Resistance	nelund	Filed: No Date	Pat. #: 1343493
Type 2 Diabetes, Hyperlipidemia and Hyperuricemia		Serial #: 01987124.3	Expires: 11/28/2021
Type 2 2 mootes, 1.Jpennpratum and 1.Jpenaricem		Conf #: None	2.44.00.11/20/2021
Title: Use of (-)-(3-Halomethylphenoxy)(4-Halophenyl)	Italy	Status: Issued	Issued: 10/31/2012
Acetic Acid Derivatives for Treatment of Insulin Resistance	,	Filed: No Date	Pat. #: 1343493
Type 2 Diabetes, Hyperlipidemia and Hyperuricemia		Serial #: 01987124.3	Expires: 11/28/2021
71 7 71 1 71		Conf #: None	1
Title: Use of (-)-(3-Halomethylphenoxy)(4-Halophenyl)	Monaco	Status: Issued	Issued: 10/31/2012
Acetic Acid Derivatives for Treatment of Insulin Resistance		Filed: No Date	Pat. #: 1343493
Type 2 Diabetes, Hyperlipidemia and Hyperuricemia		Serial #: 01987124.3	Expires: 11/28/2021
		Conf #: None	
Title: Use of (-)-(3-Halomethylphenoxy)(4-Halophenyl)	Netherlands	Status: Issued	Issued: 10/31/2012
Acetic Acid Derivatives for Treatment of Insulin Resistance		Filed: No Date	Pat. #: 1343493
Type 2 Diabetes, Hyperlipidemia and Hyperuricemia		Serial #: 01987124.3	Expires: 11/28/2021
		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-	US	Status: Issued	Issued: 9/23/2003
HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 11/28/2000	Pat. #: 6624194
TREATMENT OF INSULIN RESISTANCE, TYPE 2		Serial #: 09/724,788	Expires: 6/4/2019
DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA		Conf #: None	
Title: USE OF (-) (3-TRIHALOMETHYLPHENOXY)	US	Status: Issued	Issued: 8/18/2009
(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR		Filed: 3/4/2003	Pat. #: 7576131
TREATMENT OF INSULIN RESISTANCE, TYPE 2		Serial #: 10/382,186	
DIABETES HYPERLIPIDEMIA AND HYPERURICEMIA		Conf #: None	
Title: Use of (-)(3-Trihalomethylphenoxy) (4-Halophenyl)	US	Status: Issued	Issued: 7/9/2013
Acetic Acid Derivatives for Treatment of Insulin Resistance,		Filed: 3/28/2012	Pat. #: 8481597
Type 2 Diabetes and Hyperlipidemia		Serial #: 13/432,905	
		Conf #: 9090	
Title: Use of (-)(3-Trihalomethylphenoxy)(4-Halophenyl)	US	Status: Issued	Issued: 12/11/2012
Acetic Acid Derivatives for Treatment of Insulin Resistance,		Filed: 7/16/2009	Pat. #: 8329749
Type 2 Diabetes and Hyperlipidemia		Serial #: 12/504,061	
		Conf #: None	

THI.	6. 4	Status, Filing Date,	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: METHODS AND REAGENTS FOR DIAGNOSIS	US	Status: Issued	Issued: 12/5/2006
AND TREATMENT OF DIABETES		Filed: 12/2/2002	Pat. #: 7144985
		Serial #: 10/308,393	
		Conf #: None	7 1 11/12/2007
Title: METHODS AND REAGENTS FOR DIAGNOSIS	US	Status: Issued	Issued: 11/13/2007
AND TREATMENT OF DIABETES		Filed: 11/1/2006	Pat. #: 7294698
		Serial #: 11/591,992	
		Conf #: None	
Title: COMPOSITIONS AND METHODS FOR	US	Status: Issued	Issued: 3/31/2009
DIAGNOSING AND TREATING DIABETES, INSULIN		Filed: 12/16/2002	Pat. #: 7510851
RESISTANCE AND DYSLIPIDEMIA		Serial #: 10/321,204	
		Conf #: None	
Title: SUBSTITUTED PHENYLACETIC ACIDS	China	Status: Issued	Issued: 9/19/2007
		Filed: 3/19/2003	Pat. #: ZL03811039.3
		Serial #: 3811039.3	
		Conf #: None	
Title: SUBSTITUTED PHENYLACETIC ACIDS	EPO	Status: Pending	
		Filed: 3/19/2003	
		Serial #: 03736445.2	
		Conf #: None	
Title: SUBSTITUTED PHENYLACETIC ACIDS	India	Status: Pending	
		Filed: 3/19/2003	
		Serial #: 3020/DELNP/20	
		04	
		Conf #: None	
Title: SUBSTITUTED PHENYLACETIC ACIDS	US	Status: Issued	Issued: 7/18/2006
		Filed: 3/19/2003	Pat. #: 7078421
		Serial #: 10/394,487	Expires: 11/28/2023
		Conf #: None	2.1p11001 1112012020
Title: SUBSTITUTED PHENYLACETIC ACIDS	US	Status: Issued	Issued: 1/5/2010
The sobstite in the transfer temps		Filed: 1/4/2006	Pat. #: 7642358
		Serial #: 11/326,616	1 ut. 11. 70 12330
		Conf #: None	
		Colli #. Nolle	

Title	Comba	Status, Filing Date.	Pat/Reg No.,
Title: ALPHA(TRIFLUOROMETHYL SUBSTITUTED	US Country	App. Serial No. Status: Issued	Issue/Reg Date Issued: 5/13/2008
ARYLOXY, ARYLAMINO, ARYLTHIO OR	US	Filed: 2/17/2005	Pat. #: 7371888
ARYLMETHYL)-TRIFLUOROMETHYLSUBSTITUTED		Serial #: 11/061,302	Expires: 8/4/2025
PHENYLACETIC ACIDS AND DERIVATIVES AS		Conf #: None	LAPHOS. 0/4/2023
ANTIDIABETIC AGENTS		Com #. None	
Title: ISOLATED ISLET BETACELL TWO-PORE	US	Status: Issued	Issued: 5/30/2006
DOMAIN POTASSIUM CHA		Filed: 6/10/2003	Pat. #: 7053180
BOMENTO MODICINE CHIL		Serial #: 10/459,190	144.11.7000100
		Conf #: None	
Title: POLYNUCLEOTIDES ENCODING POTASSIUM	US	Status: Issued	Issued: 2/17/2009
CHANNELS		Filed: 3/3/2006	Pat. #: 7491533
		Serial #: 11/367,182	
		Conf #: None	
Title: Resolution of alpha-(Phenoxy) Phenylacetic Acid	Canada	Status: Pending	
1 1		Filed: No Date	
		Serial #: 2529774	
		Conf #: None	
Title: RESOLUTION OF ALPHA-	China	Status: Issued	Issued: 8/12/2009
(PHENOXY)PHENYLACETIC ACID DERIVATIVES		Filed: 6/18/2004	Pat. #: 200480021323.3
		Serial #: 2.00E+11	
		Conf #: None	
Title: RESOLUTION OF ALPHA-	India	Status: Pending	
(PHENOXY)PHENYLACETIC ACID DERIVATIVES		Filed: 6/18/2004	
		Serial #:	
		6094/DELNP/2005	
		Conf #: None	
Title: Resolution of alpha-(Phenoxy)phenylacetic acid	South Korea	Status: Issued	Issued:
Derivatives		Filed: No Date	Pat. #: 10-
		Serial #: 10-2005-	1073742
		7024492	
		Conf #: None	

Title	Comba	Status, Filing Date,	Pat/Reg No.,
Title: RESOLUTION OF ALPHA-	Country Mexico	App. Serial No. Status: Pending	Issue/Reg Date
(PHENOXY)PHENYLACETIC ACID DERIVATIVES	WICAICO	Filed: 6/18/2004	
(THENOXI)THENTENEETIC NCID DERIVATIVES		Serial #: PA/a/2005/013981	
		Conf #: None	
Title: RESOLUTION OF ALPHA-(PHENOXY)	US	Status: Issued	Issued: 4/3/2007
PHENYLACETIC ACID DERIVATIVES		Filed: 9/4/2003	Pat. #: 7199259
		Serial #:	
		10/656,567	
		Conf #: None	
Title: PANCREATIC ISLET TRANSCRIPTION FACTOR	US	Status: Issued	Issued: 7/29/2008
AND USES THEREOF		Filed: 5/2/2005	Pat. #: 7405289
		Serial #: 10/533,593	
		Conf #: None	
Title: METHODS OF DIAGNOSING AND TREATING	Japan	Status: Pending	
DIABETES AND INSULIN RESISTANCE		Filed: 6/5/2003	
		Serial #: 2004-	
		510718	
		Conf #: None	
Title: METHODS OF DIAGNOSING AND TREATING	Japan	Status: Pending	
OBESITY, DIABETES AND INSULIN RESISTANCE		Filed: 6/15/2005	
		Serial #: 2007-516737	
THE ACTUADO OF DATE OF ORDER OF THE PERSON		Conf #: None	
Title: METHODS OF DIAGNOSING & TREATING	Japan	Status: Pending	
DIABETES AND INSULIN RESISTANCE		Filed: 7/7/2005	
		Serial #: 2007-520559	
T.A., METHODO OF DIA ONOGRACIAND TREATRIC	Issan	Conf #: None	Alamadanada
Title: METHODS OF DIAGNOSING AND TREATING	Japan	Status:	Abandoned:
OBESITY, DIABETES AND INSULIN RESISTANCE		Abandoned Filed: 7/7/2005	
		Serial #: 2007-521515	
		Conf #: None	

		Status, Filing Date,	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: CD39L3 AND ITS ROLE IN DIABETES	US	Status: Issued	Issued: 7/7/2009
		Filed: 4/10/2006	Pat. #: 7556930
		Serial #: 11/402,142	
		Conf #: None	
Title: METHODS AND COMPOSITIONS FOR TREATING	US	Status: Issued	Issued: 8/8/2006
AND DIAGNOSING DIABETES AND RELATED		Filed: 3/4/2004	Pat. #: 7087394
DISEASES INVOLVING BETATRP		Serial #: 10/794,897	
		Conf #: None	
Title: COMPOSITIONS AND METHODS OF USING	US	Status: Issued	Issued: 9/19/2006
APOPTOSIS SIGNALING KINASE RELATED KINASE		Filed: 11/3/2004	Pat. #: 7109021
(ASKRK)		Serial #: 10/980,974	
		Conf #: None	
Title: COMPOSITIONS AND METHODS OF USING	US	Status: Issued	Issued: 3/18/2008
APOPTOSIS SIGNALING KINASE RELATED KINASE		Filed: 7/17/2006	Pat. #: 7344844
(ASKRK)		Serial #: 11/488,338	
		Conf #: None	
Title: COMPOSITIONS AND METHODS OF USING	US	Status: Issued	Issued: 9/19/2006
APOPTOSIS SIGNALING KINASE RELATED KINASE		Filed: 11/3/2004	Pat. #: RE40,624
(ASKRK)		Serial #: 11/900,008	
		Conf #: None	
Title: SUBSTITUTED TRIAZOLES AS MODULATORS	US	Status: Issued	Issued: 1/29/2008
OF PPAR AND METHODS OF THEIR PREPARATION		Filed: 5/24/2005	Pat. #: 7323480
		Serial #: 11/137,678	
		Conf #: None	
Title: MODULATORS OF PPAR AND METHODS OF	US	Status: Issued	Issued: 11/24/2009
THEIR PREPARATION		Filed: 8/11/2005	Pat. #: 7622491
		Serial #: 11/202,963	
		Conf #: None	
Title: Methods for Avoiding Edema in the Treatment of	EPO	Status: Pending	
Prevention of PPARy-Responsive Diseases Including Cancer		Filed: No Date	
		Serial #: 06739211.8	
		Conf #: None	

		Status, Filing Date,	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: Methods for Avoiding Edema in the Treatment or	US	Status: Issued	Issued: 10/16/2012
Prevention of PPARy-Responsive Diseases, Including Cancer		Filed: 4/7/2008	Pat. #: 8288438
		Serial #: 11/908,952	Expires: 4/4/2029
		Conf #: None	
Title: Crystalline Solid and Amorphous Forms of (-)-	Australia	Status: Pending	
Halofenate		Filed: No Date	
		Serial #: 2006236153	
		Conf #: None	
Title: Crystalline Solid and Amorphous Forms of (-)-	US	Status: Issued	Issued: 8/13/2013
Halofenate and Methods Related Thereto		Filed: 5/11/2012	Pat. #: 8507719
		Serial #: 13/470,142	
		Conf #: 1435	
Title: Crystalline Solid and Amorphous Forms of (-)-	US	Status: Pending	
Halofenate and Methods Related Thereto		Filed: 7/10/2013	
		Serial #: 13/938,548	
		Conf #: None	
Title: CRYSTALLINE SOLID AND AMORPHOUS	Canada	Status: Pending	
FORMS OF (-)-HALOFENATE		Filed: 4/20/2006	
		Serial #: 2606279	
		Conf #: None	
Title: CRYSTALLINE SOLID AND AMORPHOUS	Colombia	Status: Pending	
FORMS OF (-)-HALOFENATE		Filed: 4/20/2006	
		Serial #: 07-	
		121.938	
		Conf #: None	
Title: CRYSTALLINE SOLID AND AMORPHOUS	Costa Rica	Status:	Abandoned:
FORMS OF (-)-HALOFENATE		Abandoned	
Notes: Rozsnyai 12.18.12 email -abandon		Filed: 4/20/2006	
		Serial #: 9516	
		Conf #: None	

		Status, Filing Date,	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: CRYSTALLINE SOLID AND AMORPHOUS	Ecuador	Status: Pending	
FORMS OF (-)-		Filed: 11/12/2007	
HALOFENATE		Serial #: SP-07-7890	
		Conf #: None	
Title: CRYSTALLINE SOLID AND AMORPHOUS	Indonesia	Status: Pending	
FORMS OF (-)-		Filed: 4/20/2006	
HALOFENATE		Serial #: W-00200703388	
		Conf #: None	
Title: CRYSTALLINE SOLID AND AMORPHOUS	Israel	Status: Allowed	Expires:
FORMS OF (-)-		Filed: 4/20/2006	4/20/2026
HALOFENATE		Serial #: 186664	
		Conf #: None	
Title: CRYSTALLINE SOLID AND AMORPHOUS	India	Status:	Abandoned:
FORMS OF (-)-		Abandoned	
HALOFENATE		Filed: 4/20/2006	
Notes: 5.31.13 SLN email – client wants to abandon		Serial #:	
		8351/DELPN/2007	
		Conf #: None	
Title: CRYSTALLINE SOLID AND AMORPHOUS	Republic of Korea	Status: Pending	
FORMS OF (-)-	•	Filed: 4/20/2006	
HALOFENATE		Serial #: 10-2007-	
		7026905	
		Conf #: None	
Title: CRYSTALLINE SOLID AND AMORPHOUS	Sri Lanka	Status: Issued	Issued: 6/10/2009
FORMS OF (-)-		Filed: 4/20/2006	Pat. #: 14691
HALOFENATE		Serial #: 14691	
		Conf #: None	
Title: Crystalline Solid and Amorphous Forms of (-)-	Mexico	Status: Pending	
Halofenate		Filed: No Date	
		Serial #:	
		MX/a/2007/012991	
		Conf #: None	

		Status, Filing Date,	Pat/Reg No
Title	Country	App. Serial No.	Issue/Reg Date
Title: Crystalline Solid and Amorphous Forms of (-)-	Nicaragua	Status: Pending	
Halofenate and Methods Related Thereto		Filed: No Date	
		Serial #: 2007-0269	
		Conf #: None	
Title: CRYSTALLINE SOLID AND AMORPHOUS	Philippines	Status: Pending	
FORMS OF (-)-HALOFENATE		Filed: 4/20/2006	
		Serial #: 1-2007-502334	
		Conf #: None	
Title: CRYSTALLINE SOLID AND AMORPHOUS	Ukraine	Status: Pending	
FORMS OF (-)-		Filed: 4/20/2006	
HALOFENATE		Serial #:a200712893	
		Conf #: None	
Title: Crystalline Solid and Amorphous Forms of (-)-	US	Status: Issued	Issued: 6/19/2012
Halofenate and Methods Related Thereto		Filed: 4/20/2006	Pat. #: 8,203,019
		Serial #: 11/408,609	Expires: 7/20/2029
		Conf #: None	
Title: Methods for Avoiding Edema in the Treatment of	EPO	Status: Pending	
Prevention of PPARy-Responsive Diseases Including Cancer		Filed: No Date	
		Serial #: 06739286.0	
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	EPO	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Austria	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Bosnia and	Status: Issued	Issued:
Halofenate and Intermediates Thereof	Herzegovina	Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	

Title	Comba	Status, Filing Date,	Pat/Reg No.,
Title: Process for the Stereoselective Preparation of (-)-	Country  Belgium	App. Serial No. Status: Issued	Issue/Reg Date Issued:
Halofenate and Intermediates Thereof	Deigium	Filed: No Date	Pat. #: 1940387
Transferate and intermediates thereof		Serial #:	Expires:
		06815150.5	9/21/2026
		Conf #: None	7/21/2020
Title: Process for the Stereoselective Preparation of (-)-	Bulgaria	Status: Issued	Issued:
Halofenate and Intermediates Thereof	Duigaria	Filed: No Date	Pat. #: 1940387
Transferate and intermediates thereof		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	Expires. 7/21/2020
Title: PROCESS FOR THE STEREOSELECTIVE	Brazil	Status: Pending	
PREPARATION OF (-)-HALOFENATE AND	Diuzii	Filed: 9/21/2006	Expires:
DERIVATIVES THEREOF		Serial #:	9/21/2026
DERIVATIVES THEREOF		PI0616188-0	7/21/2020
		Conf #: None	
Title: PROCESS FOR THE STEREOSELECTIVE	Canada	Status: Pending	
PREPARATION OF (-)-HALOFENATE AND		Filed: 9/21/2006	Expires:
DERIVATIVES THEREOF		Serial #: 2623350	9/21/2026
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Switzerland and	Status: Issued	Issued:
Halofenate and Intermediates Thereof	Liechtens	Filed: No Date	Pat. #: 1940387
		Serial #:	Expires:
		06815150.5	9/21/2026
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Cyprus	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Czech	Status: Issued	Issued:
Halofenate and Intermediates Thereof	Republic	Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	

		Status, Filing Date,	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: Process for the Stereoselective Preparation of (-)-	Germany	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #:	Expires: 9/21/2026
		06815150.5	
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Denmark	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #:	Expires:9/21/2026
		06815150.5	
		Conf #: None	
Title: PROCESS FOR THE STEREOSELECTIVE	EAPO	Status: Pending	
PREPARATION OF (-)-HALOFENATE AND		Filed: 9/21/2006	Expires: 9/21/2026
DERIVATIVES THEREOF		Serial #:	
		200800884	
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Estonia	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #:	Expires: 9/21/2026
		06815150.5	
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	EPO	Status: Issued	Issued: 11/28/2012
Halofenate and Intermediates Thereof		Filed: 9/21/2006	Pat. #: 1940387
		Serial #:	Expires: 9/21/2026
		06815150.5	
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Spain	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	•

Tist.	Constan	Status, Filing Date.	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: Process for the Stereoselective Preparation of (-)-	Finland	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	
Titles Ducases for the Starges elective Ducases in of ()	France	Status: Issued	Issued:
Title: Process for the Stereoselective Preparation of (-)- Halofenate and Intermediates Thereof	France	Filed: No Date	Pat. #: 1940387
Traiotenate and intermediates Thereor		Serial #: 06815150.5	
		Conf #: None	Expires: 9/21/2026
Title: Process for the Stereoselective Preparation of (-)-	United Kingdom	Status: Issued	Issued:
Halofenate and Intermediates Thereof	Office Kingdom	Filed: No Date	Pat. #: 1940387
Transferate and intermediates Thereof		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	Expires. 3/21/2020
Title: Process for the Stereoselective Preparation of (-)-	Greece	Status: Issued	Issued:
Halofenate and Intermediates Thereof	Giccc	Filed: No Date	Pat. #: 1940387
Transferance and intermediates Thereof		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	Expires: 7/21/2020
Title: Process for the Stereoselective Preparation of (-)-	Hong Kong	Status: Granted	
Halofenate and Intermediates Thereof	Tions Tions	Filed: 9/21/2006	Expires: 9/21/2026
22000		Serial #: 08114045.8	p. 45: 5/21:2020
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Croatia	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	1
Title: Process for the Stereoselective Preparation of (-)-	Hungary	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	•
Title: PROCESS FOR THE STEREOSELECTIVE	Indonesia	Status: Granted	
PREPARATION OF (-)-HALOFENATE AND		Filed: 9/21/2006	Expires:
INTERMEDIATES THEREOF		Serial #: W-00200800946	9/21/2026
		Conf #: None	

Title	Comba	Status, Filing Date,	Pat/Reg No., Issue/Reg Date
	Country  Ireland	App. Serial No. Status: Issued	Issued:
Title: Process for the Stereoselective Preparation of (-)- Halofenate and Intermediates Thereof	Ireland	Filed: No Date	Pat. #: 1940387
Halorenate and intermediates Thereof			
		Serial #: 06815150.5 Conf #: None	Expires: 9/21/2026
Title: Discover for the Stanger elective Discoveries of ()	Iona al	<del>-</del>	
Title: Process for the Stereoselective Preparation of (-)- Halofenate and Intermediates Thereof	Israel	Status: Allowed	Fraince 0/21/2026
Halorenate and intermediates Thereor		Filed: 9/21/2006	Expires: 9/21/2026
		Serial #: 190325	
T'A., DDOODES FOR THE STERFOSEL FOTIVE	T., 1!.	Conf #: None	
Title: PROCESS FOR THE STEREOSELECTIVE	India	Status: Pending	F ' 0/01/0006
PREPARATION OF (-)-HALOFENATE AND		Filed: 9/21/2006	Expires: 9/21/2026
DERIVATIVES THEREOF		Serial #:	
		2786/DELPN/2008	
The property of the property o	7 1 1	Conf #: None	7 1
Title: Process for the Stereoselective Preparation of (-)-	Iceland	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Italy	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	
Title: PROCESS FOR THE STEREOSELECTIVE	Japan	Status: Pending	
PREPARATION OF (-)-HALOFENATE AND		Filed: 9/21/2006	Expires: 9/21/2026
DERIVATIVES THEREOF		Serial #: 2008-532404	
		Conf #: None	
Title: PROCESS FOR THE STEREOSELECTIVE	Republic of Korea	Status: Allowed	
PREPARATION OF (-)-HALOFENATE AND		Filed: 9/21/2006	Expires: 9/21/2026
DERIVATIVES THEREOF		Serial #: 10-2008-7009709	
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Lithuania	Status: Issued	Issued: 1/25/2013
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	

Tid.	Conta	Status, Filing Date,	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: Process for the Stereoselective Preparation of (-)- Halofenate and Intermediates Thereof	EPO	Status: Issued	Issued:
Halolenate and intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
Tide Decree for the Chance leading Decree of ()	Lateria	Conf #: None	I J.
Title: Process for the Stereoselective Preparation of (-)-	Latvia	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
mid p e d o d d d d d e d d e	14	Conf #: None	T 1
Title: Process for the Stereoselective Preparation of (-)-	Monaco	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Macedonia	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Mexico	Status: Issued	Issued: 3/21/2012
Halofenate and Intermediates Thereof		Filed: 9/21/2006	Pat. #: 297393
		Serial #:	Expires: 9/21/2026
		MX/a/2008/003796	
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Netherlands	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	•
Title: Process for the Stereoselective Preparation of (-)-	Philippines	Status: Allowed	
Halofenate and Intermediates Thereof	11	Filed: 9/21/2006	Expires: 9/21/2026
		Serial #: 1-2008-500722	1
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Poland	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	

		Status, Filing Date,	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: Process for the Stereoselective Preparation of (-)-	Portugal	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Romania	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Yugoslavia	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	•
Title: Process for the Stereoselective Preparation of (-)-	Sweden	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	•
Title: PROCESS FOR THE STEREOSELECTIVE	Singapore	Status: Pending	
PREPARATION OF (-)-HALOFENATE AND		Filed: 9/21/2006	Expires: 9/21/2026
INTERMEDIATES THEREOF		Serial #: 200802261-8	•
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Slovenia	Status: Issued	Issued:
Halofenate and Intermediates Thereof		Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	
Title: Process for the Stereoselective Preparation of (-)-	Slovak Republic	Status: Issued	Issued:
Halofenate and Intermediates Thereof	•	Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	•
Title: Process for the Stereoselective Preparation of (-)-	Turkey	Status: Issued	Issued:
Halofenate and Intermediates Thereof	·	Filed: No Date	Pat. #: 1940387
		Serial #: 06815150.5	Expires: 9/21/2026
		Conf #: None	_

TT+13	a	Status, Filing Date,	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: PROCESS FOR THE STEREOSELECTIVE	Viet Nam	Status: Pending	F
PREPARATION OF (-)-HALOFENATE AND		Filed: 9/21/2006	Expires: 9/21/2026
DERIVATIVES THEREOF		Serial #: 1-2008-	
		00955	
m'4 PROCECC FOR THE CHERROCAFT FOTHER	0 1 4 6 '	Conf #: None	T 1.0/20/2000
Title: PROCESS FOR THE STEREOSELECTIVE	South Africa	Status: Issued	Issued: 9/30/2009
PREPARATION OF (-)-HALOFENATE AND		Filed: 9/21/2006	Pat. #:
INTERMEDIATES THEREOF		Serial #: 2008/03329	2008/03329
		Conf #: None	Expires: 9/21/2026
Title: RESOLUTION OF ALPHA-(PHENOXY)	Canada	Status: Pending	
PHENYLACETIC ACID DERIVATIVES WITH		Filed: 9/21/2006	
NAPHTHYL-ALKYLAMINES		Serial #: 2623355	
		Conf #: None	
Title: Resolution of Alpha-(Phenoxy) Phenylacetic Acid	China	Status: Issued	Issued: 4/3/2013
Derivatives with Naphthyl-Alkylamines		Filed: No Date	Pat. #:
		Serial #: 200680039060.8	101495427B
		Conf #: None	Expires: 9/21/2026
Title: RESOLUTION OF ALPHA-(PHENOXY)	China	Status: Pending	
PHENYLACETIC ACID DERIVATIVES WITH		Filed: 9/21/2006	
NAPHTHYL-ALKYLAMINES		Serial #: 2.01E+11	
		Conf #: None	
Title: RESOLUTION OF ALPHA-(PHENOXY)	US	Status: Issued	Issued: 10/7/2008
PHENYLACETIC ACID DERIVATIVES WITH		Filed: 9/20/2006	Pat. #: 7432394
NAPHTHYL-ALKYLAMINES		Serial #: 11/525,201	
		Conf #: None	
Title: Methods of Reducing Small, Dense LDL Particles	Brazil	Status: Pending	
		Filed: No Date	
		Serial #: PI0920170-0	
		Conf #: None	
Title: METHODS OF REDUCING SMALL, DENSE LDL	Canada	Status: Pending	
PARTICLES		Filed: 10/14/2009	
		Serial #: 2740874	
		Conf #: None	

Title	Country	Status, Filing Date, App. Serial No.	Pat/Reg No., Issue/Reg Date
Title: Methods of Reducing Small, Dense LDL Particles	China	Status: Pending	assucing said
That would by restricting order, 2011 2221 miles		Filed: No Date	
		Serial #: 200980144827.7	
		Conf #: None	
Title: METHODS OF REDUCING SMALL, DENSE LDL	EPO	Status: Pending	
PARTICLES		Filed: 10/14/2009	
		Serial #: 09821200.4	
		Conf #: None	
Title: Methods of Reducing Small, Dense LDL Particles	Hong Kong	Status: Pending	
		Filed: 10/14/2009	
		Serial #: 11114028.4	
		Conf #: None	
Title: METHODS OF REDUCING SMALL, DENSE LDL	India	Status: Pending	
PARTICLES		Filed: 5/5/2011	
		Serial #:	
		3077/CHENP/2011	
		Conf #: None	
Title: METHODS OF REDUCING SMALL, DENSE LDL	Japan	Status: Pending	
PARTICLES		Filed: 10/14/2009	
		Serial #: 2011-532217	
		Conf #: None	
Title: METHODS OF REDUCING SMALL, DENSE LDL	Republic of Korea	Status: Pending	
PARTICLES		Filed: 10/14/2009	
		Serial #: 10-2011-7011217	
THE ACTUARY OF REDUCENCE SHALL REVEST ST	)	Conf #: None	
Title: METHODS OF REDUCING SMALL, DENSE LDL	Mexico	Status: Pending	
PARTICLES		Filed: 10/14/2009	
		Serial #:	
		MX/a/2011/004077	
		Conf #: None	

		Status, Filing Date,	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: Methods of Reducing Small, Dense LDL Particles	Taiwan	Status: Pending	
		Filed: No Date	
		Serial #: 098135183	
		Conf #: None	
Title: METHODS OF REDUCING SMALL, DENSE LDL	US	Status: Pending	
PARTICLES		Filed: 10/15/2009	
		Serial #: 12/579,996	
		Conf #: None	
Title: PROCESS FOR THE PREPARATION OF (-)-(4-	US	Status: Pending	
CHLOROPHENYL)-(3-		Filed: 3/16/2012	
TRIFLUOROMETHYLPHENOXY)-ACETIC ACID 2-		Serial #: 13/422,838	
ACETYLAMINO-ETHYL ESTER		Conf #: 1735	
Title: PROCESS FOR THE PREPARATION OF (-)-(4-	US	Status: Pending	
CHLOROPHENYL)-(3-		Filed: 4/3/2009	
TRIFLUOROMETHYLPHENOXY)-ACETIC ACID2-		Serial #: 12/417,671	
ACETYLAMINO-ETHYL ESTER		Conf #: None	
Title: Methods for Treating Hyperuricemia in Patients with	PCT	Status: Pending	
Gout Using Halofenate or Halofenic Acid and a Second		Filed: 11/4/2011	
Urate-Lowering Agent		Serial #: PCT/US11/059394	
		Conf #: None	
Title: Methods for Treating Hyperuricemia in Patients with	US	Status: Pending	
Gout Using Halofenate or Halogenic Acid and a Second		Filed: 11/2/2012	
Urate-Lowering Agent		Serial #: 13/668,164	
		Conf #: 8296	
Title: Methods for Treating Gout in Patient Subpopulations	PCT	Status: Pending	
		Filed: 11/4/2011	
		Serial #: PCT/US11/059425	
		Conf #: 7067	
Title: Methods for Treating Gout in Patient Subpopulations	US	Status: Pending	
		Filed: 11/2/2012	
		Serial #: 13/668,024	
		Conf #: 6642	

TF-1	G	Status, Filing Date,	Pat/Reg No.,
Title	Country	App. Serial No.	Issue/Reg Date
Title: METHOD FOR TREATING GOUT FLARES	PCT	Status: Pending	
		Filed: 11/4/2011	
		Serial #: PCT/US11/59433	
		Conf #: None	
Title: Methods for Treating Gout Flares	US	Status: Pending	
		Filed: 11/2/2012	
		Serial #: 13/668,003	
		Conf #: 7094	
Title: DCC Mediated Coupling for Halofenate Manufacture	PCT	Status: Pending	
• •		Filed: 1/18/2013	
		Serial #: PCT/US13/22213	
		Conf #: None	
Title: DCC Mediated Coupling for Halofenate Manufacture	US	Status: Pending	
		Filed: 1/18/2013	
		Serial #: 13/745,315	
		Conf #: 8124	
Title: Method for Treating Hyperuricemia in Patients with	PCT	Status: Pending	
Gout Using Halofenate or Halofenic Acid and an Anti-		Filed: 4/12/2013	
Inflammatory Agent		Serial #: PCT/US13/36474	
• 0		Conf #: None	
Title: Method for Treating Hyperuricemia in Patients with	US	Status: Pending	
Gout Using Halofenate or Halofenic Acid and an Anti-		Filed: 4/12/2013	
Inflammatory Agent		Serial #: 13/862,262	
		Conf #: None	
Method of solution overcoating with gelling polymer	US	Status: Issued	Issued: 4/14/98
<i>C C</i> 01 7		Filed: 9/20/96	Pat. #: 5738876
		Serial #: 08/713.138	

Title	Country	Application Number	Application Date	Patent Number
OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF	US	12/414639	3/30/2009	
OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF	Canada	2719507	3/30/2009	
OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF	China P.R.	200980110894.7	3/30/2009	
OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF	ЕРО	09727673.7	3/30/2009	
OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF	India	3940/KOLNP/2010	3/30/2009	
OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF	Japan	2011-502137	3/30/2009	
Oxymethylene Aryl Compounds and Uses Therof	Hong Kong	11108349.8	3/30/2009	
Aryl GPR119 Agonists And Uses Thereof	Canada	2727174	6/16/2009	
Aryl GPR119 Agonists And Uses Thereof	India	4684/KOLNP/2010	6/16/2009	
N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	US	12/171209	7/10/2008	8183381
N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	US	13/463617	5/3/2012	
N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	Canada	2693169	7/10/2008	
N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 RECEPTOR FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS (AS AMENDED)	China P.R.	200880025293.1	7/10/2008	

Title	Country	Application Number	Application Date	Patent Number
N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 RECEPTOR FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	EPO	08826604.4	7/10/2008	
N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 RECEPTOR FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS (AS AMENDED)	India	201/KOLNP/2010	7/10/2008	
N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 RECEPTOR FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS (AS AMENDED)	Japan	2010-517080	7/10/2008	
N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 RECEPTOR FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	Hong Kong	10108838.7	7/10/2008	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	US	12/582610	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Argentina	20090104033	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Taiwan	098135635	10/21/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Australia	2009307656	10/20/2009	

Title	Country	Application Number	Application Date	Patent Number
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Brazil	PI0920237-4	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Canada	2740366	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Chile	899-2011	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	China P.R.	20098141384.6	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Colombia	11-058.452	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Costa Rica	2011-0201	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Eurasian Pat. Convention	201170504	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Ecuador	SP-11-10989	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Egypt	569/2011	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	EPO	09744008.5	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Guatemala	S2011-000097	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Honduras	2011-000982	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Indonesia	W00201101439	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Israel	212144	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	India	2060/KOLNP/2011	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Japan	2011-532337	10/20/2009	

Title	Country	Application Number	Application Date	Patent Number
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	South Korea	10-2011-7009622	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Sri Lanka	16257	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Mexico	MX/a/2011/004125	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Malaysia	PI 2011001556	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Nigeria	NG/C/2011/359	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Nicaragua	2011-000075	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	New Zealand	592603	10/20/2009	592603
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Philippines	1-2011-500770	10/20/2009	
ARYLGPR120 RECEPTOR AGONISTS AND USES THEREOF	Singapore	201102485-8	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	El Salvador	2011003885	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Ukraine	a 2011 06189	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Vietnam	1-2011-01219	10/20/2009	
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	South Africa	2011/02815	10/20/2009	2011/02815
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF	Hong Kong	12100969.3	10/20/2009	
5-ETHYL-2-{4-[4-(4-TETRAZOL-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE	US	11/964461	12/26/2007	7638541

Title	Country	Application Number	Application Date	Patent Number
2,4-DISUBSTITUTED THIAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF (As Amended)	US	12/541865	8/14/2009	8227495
HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	US	12/619577	11/16/2009	8288384
HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	US	13/612451	9/12/2012	
HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	US	13/743166	1/16/2013	
Heterocyclic Receptor Agonists For The Treatment Of Diabetes And Metabolic Disorders	Argentina	07 01 05977	12/28/2007	
HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	Chile	3841-2007	12/27/2007	
Heterocyclic Receptors Agonists For The Treatment Of Diabetes And Metabolic Disorders	Taiwan	096150669	12/27/2007	
HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	Australia	2007339772	12/27/2007	
HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	Brazil	P10720675-5	12/27/2007	
HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	Canada	2672725	12/27/2007	
Heterocyclic Receptors Agonists For The Treatment Of Diabetes And Metabolic Disorders	China P.R.	200780048023.8	12/27/2007	

Title	Country	Application Number	Application Date	Patent Number
HETEROCYCLIC RECEPTOR AGONISTS	Eurasian Pat.	200900896	12/27/2007	016720
FOR THE TREATMENT OF DIABETES AND	Convention			
METABOLIC DISORDERS				
HETEROCYCLIC RECEPTOR AGONISTS	Russian			016720
FOR THE TREATMENT OF DIABETES AND	Federation			
METABOLIC DISORDERS	_			
HETEROCYCLIC RECEPTOR AGONISTS	EPO	07869989.9	12/27/2007	
FOR THE TREATMENT OF DIABETES AND				
METABOLIC DISORDERS		77700400004776	10/07/00/07	
HETEROCYCLIC RECEPTOR AGONISTS	Indonesia	W00200901776	12/27/2007	
FOR THE TREATMENT OF DIABETES AND				
METABOLIC DISORDERS	T 1	100207	12/25/2005	
HETEROCYCLIC RECEPTOR AGONISTS	Israel	199397	12/27/2007	
FOR THE TREATMENT OF DIABETES AND				
METABOLIC DISORDERS	т 1'	2251 W.O. NID/2000	12/25/2005	
HETEROCYCLIC RECEPTOR AGONISTS	India	2271/KOLNP/2009	12/27/2007	
FOR THE TREATMENT OF DIABETES AND				
METABOLIC DISORDERS  HETEROGYCLIC RECEPTOR A CONJECTS	Innon	2000 544271	12/27/2007	
HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND	Japan	2009-544271	12/27/2007	
METABOLIC DISORDERS				
HETEROCYCLIC RECEPTOR AGONISTS	South Korea	10-2009-7015460	12/27/2007	
FOR THE TREATMENT OF DIABETES AND	South Korca	10-2007-7013-100	12/2/12007	
METABOLIC DISORDERS				
HETEROCYCLIC RECEPTOR AGONISTS	Mexico	MX/a/2009/007023	12/27/2007	305255
FOR THE TREATMENT OF DIABETES AND	Monteo	1111111120071007023	12/12/12/00/	365255
METABOLIC DISORDERS				
HETEROCYCLIC RECEPTOR AGONISTS	New Zealand	577996	12/27/2007	577996
FOR THE TREATMENT OF DIABETES AND				
METABOLIC DISORDERS				
HETEROCYCLIC RECEPTOR AGONISTS	Philippines	1-2009-501304	12/27/2007	
FOR THE TREATMENT OF DIABETES AND				
METABOLIC DISORDERS				

Title	Country	Application Number	Application Date	Patent Number
HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	Singapore	200904206-0	12/27/2007	153459
HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	Vietnam	1-2009-01375	12/27/2007	
Heterocyclic Receptors Agonists For The Treatment Of Diabetes And Metabolic Disorders	South Africa	2009/04281	12/27/2007	2009/04281
HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS	Hong Kong	10104032.0	12/27/2007	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	US	12/641263	12/17/2009	8309600
GPR120 RECEPTOR AGONISTS AND USES THEREOF	US	13/646409	10/5/2012	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Argentina	20090104925	12/16/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Taiwan	098143781	12/18/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Australia	2009335797	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Brazil	PCT/US2009/068576; PI0922483-1	12/17/2009; 12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Canada	2746762	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	China P.R.	200980156131.6	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Colombia	11.076.781	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Costa Rica	2011-0344	12/17/2009	

Title	Country	Application Number	Application Date	Patent Number
GPR120 Receptor Agonists and Uses Thereof	Eurasian Pat. Convention	201190053	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Ecuador	SP-11-11149	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Egypt	PCT 1025/2011	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	EPO	09796212.0	12/17/2009	2367793
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Guatemala	S2-011-0178	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Honduras	2011-001703	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Indonesia	W00201102283	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Israel	213569	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	India	2602/KOLNP/2011	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Japan	2011-542451	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	South Korea	10-2011-7016300	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Sri Lanka	16317	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Mexico	MX/a/2011/006574	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Malaysia	PI 2011002736	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Nigeria	NG/C/2011/380	12/17/2009	NG/C/2011/380
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Nicaragua	2011-000126	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	New Zealand	593906	12/17/2009	

Title	Country	Application Number	Application Date	Patent Number
GPR120 Receptor Agonists and Uses Thereof	Philippines	1-2011-501216	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	Singapore	201104313-0	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	El Salvador	2011003954	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	Ukraine	a 2011 08818	12/17/2009	
GPR120 Receptor Agonists	Vietnam	1-2011-01860	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	South Africa	2011/04570	12/17/2009	2011/04570
GPR120 Receptor Agonists and Uses Thereof	Chile	1497-2011	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	EPO	12174635.8	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	Hong Kong	12102249.1	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	Belgium	09796212.0	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	Switzerland	09796212.0	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	Germany	09796212.0	12/17/2009	602009014505
GPR120 Receptor Agonists and Uses Thereof	Spain	09796212.0	12/17/2009	
SUBSTITUTED TETRAZOL-1-YL-	US	12/886470	9/20/2010	8410127
PHENOXYMETHYL-THIAZOL-2-YL-				
PIPERIDINYL-PYRIMIDINE SALTS				
SUBSTITUTED TETRAZOL-1-YL-	US	13/853000	3/28/2013	
PHENOXYMETHYL-THIAZOL-2-YL-				
PIPERIDINYL-PYRIMIDINE SALTS				
SUBSTITUTED TETRAZOL-1-YL-	Argentina	20100103461	9/22/2010	
PHENOXYMETHYL-THIAZOL-2-YL-				
PIPERIDINYL-PYRIMIDINE SALTS				
SUBSTITUTED TETRAZOL-1-YL-	Taiwan	099133406	9/30/2010	
PHENOXYMETHYL-THIAZOL-2-YL-				
PIPERIDINYL-PYRIMIDINE SALTS				
SUBSTITUTED TETRAZOL-1-YL-	Canada	2775840	9/20/2010	
PHENOXYMETHYL-THIAZOL-2-YL-				
PIPERIDINYL-PYRIMIDINE SALTS	au	404000040000	0.10.0.10.0.1.0	
SUBSTITUTED TETRAZOL-1-YL-	China P.R.	201080042922.9	9/20/2010	
PHENOXYMETHYL-THIAZOL-2-YL-				
PIPERIDINYL-PYRIMIDINE SALTS				

Title	Country	Application Number	Application Date	Patent Number
SUBSTITUTED TETRAZOL-1-YL- PHENOXYMETHYL-THIAZOL-2-YL- PIPERIDINYL-PYRIMIDINE SALTS	EPO	10759779.1	9/20/2010	
SUBSTITUTED TETRAZOL-1-YL- PHENOXYMETHYL-THIAZOL-2-YL- PIPERIDINYL-PYRIMIDINE SALTS	Japan	2012-532124	9/20/2010	
SUBSTITUTED TETRAZOL-1-YL- PHENOXYMETHYL-THIAZOL-2-YL- PIPERIDINYL-PYRIMIDINE SALTS	Hong Kong	13101540.8	9/20/2010	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	US	12/817116	6/16/2010	8299117
GPR120 RECEPTOR AGONISTS AND USES THEREOF	US	13/645287	10/4/2012	8476308
GPR120 RECEPTOR AGONISTS AND USES THEREOF	PCT	US2010/038906	6/16/2010	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Argentina	20100102138	6/16/2010	
GPR120 Receptor Agonists and Uses Thereof	Taiwan	099119798	6/17/2010	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	GCC	2010/16097	6/16/2010	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Jordan	203/2010	6/17/2010	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Panama	88804-01	6/17/2010	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Pakistan	532/2010	6/16/2010	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Thailand	1001000900	6/17/2010	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Uruguay	32719	6/17/2010	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Venezuela	000978-2010	6/17/2010	

Title	Country	Application Number	Application Date	Patent Number
CDD130 DECEDTOD ACQNIGTS AND LIGHS	Consider	3001103	(4(0010	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	Canada	2801182	6/16/2010	
GPR120 RECEPTOR AGONISTS AND USES	EPO	10731862.8	6/16/2010	
THEREOF	EIO	107,31002.0	0/10/2010	
GPR120 RECEPTOR AGONISTS AND USES	Japan	2013-515309	6/16/2010	
THEREOF	Jupan	2013 31330)	0/10/2010	
COMPOSITIONS OF 5-ETHYL-2-{4-[4-(4-	US	13/165651	6/21/2011	
TETRAZOL-1-YL-PHENOXYMETHYL)-		10,100,001	0.21.2011	
THIAZOL-2-YL]-PIPERIDIN-1-YL}-				
PYRIMIDINE				
COMPOSITIONS OF 5-ETHYL-2-{4-[4-(4-	PCT	US2011/040972	6/17/2011	
TETRAZOL-1-YL-PHENOXYMETHYL)-				
THIAZOL-2-YL]-PIPERIDIN-1-YL}-				
PYRIMIDINE				
COMPOSITIONS OF 5-ETHYL-2-{4-[4-(4-	Brazil	112012032248 6	6/17/2011	
TETRAZOL-1-YL-PHENOXYMETHYL)-				
THIAZOL-2-YL]-PIPERIDIN-1-YL}-				
PYRIMIDINE				
COMPOSITIONS OF 5-ETHYL-2-{4-[4-(4-	Canada	2802541	6/17/2011	
TETRAZOL-1-YL-PHENOXYMETHYL)-				
THIAZOL-2-YL]-PIPERIDIN-1-YL}-				
PYRIMIDINE  CONTROL OF SETTING A 44 44 44	CI. DD	2011000202016	(117/2014	
COMPOSITIONS OF 5-ETHYL-2-{4-[4-(4-	China P.R.	201180028394.6	6/17/2011	
TETRAZOL-1-YL-PHENOXYMETHYL)-				
THIAZOL-2-YL]-PIPERIDIN-1-YL}-				
PYRIMIDINE  COMPOSITIONS OF 5 ETHAL 2 (4 (4 (4	T. Ji.	2/07/MINAND/2012	(/17/2011	
COMPOSITIONS OF 5-ETHYL-2-{4-[4-(4-	India	2607/MUMNP/2012	6/17/2011	
TETRAZOL-1-YL-PHENOXYMETHYL)-				
THIAZOL-2-YL]-PIPERIDIN-1-YL}- PYRIMIDINE				
1 I KIMIDINE				

Title	Country	Application Number	Application Date	Patent Number
COMPOSITIONS OF 5-ETHYL-2-{4-[4-(4-TETRAZOL-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE	EPO	11728490.1	6/17/2011	
AGONISTS OF GPR131 AND USES THEREOF	US	13/495878	6/13/2012	
AGONISTS OF GPR131 AND USES THEREOF	PCT	US2012/042319	6/13/2012	
GPR120 Receptor Agonists and Uses Thereof	Norway	09796212.0	12/17/2009	
BICYCLIC AGONISTS OF GPR131 AND USES THEREOF	US	13/594598	8/24/2012	
BICYCLIC AGONISTS OF GPR131 AND USES THEREOF	PCT	US2012/052364	8/24/2012	
GPR120 Receptor Agonists and Uses Thereof	France	09796212.0	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	United Kingdom	09796212.0	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	Ireland	09796212.0	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	Italy	09796212.0	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	Netherlands	09796212.0	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	Denmark	09796212.0	12/17/2009	
GPR120 Receptor Agonists and Uses Thereof	Hong Kong	13104893.5	12/17/2009	
GPR120 RECEPTOR AGONISTS AND USES THEREOF	New Zealand	611429	12/17/2009	

## Patent Licenses

Country	Filing Date	Filing number	Grant number
ARGENTINA	09/20/2004	P040103376	
ARMENIA	09/16/2004	200600440	012241
AUSTRALIA	09/16/2004	2004285849	2004285849
AUSTRIA	09/16/2004	04816875.1	1667964
AZERBAIJAN	09/16/2004	200600440	012241
BELARUS	09/16/2004	200600440	012241
BELGIUM	09/16/2004	04816875.1	1667964
BRAZIL	09/16/2004	PI0414268-3	
BULGARIA	09/16/2004	04816875.1	1667964
CANADA	09/16/2004	2539446	
CHILE	09/20/2004	2004-2396	46502
CHINA	09/16/2004	200480033590.2	200480033590.2
CYPRUS	09/16/2004	04816875.1	1667964
CZECH REPUBLIC	09/16/2004	04816875.1	1667964
DENMARK	09/16/2004	04816875.1	1667964
ECUADOR	09/16/2004	06-6434	
EGYPT	09/16/2004	273/2006	
ESTONIA	09/16/2004	04816875.1	1667964
FINLAND	09/16/2004	04816875.1	1667964
FRANCE	09/16/2004	04816875.1	1667964
FRANCE	04/27/2009	09075188.4	2100877
GERMANY	09/16/2004	04816875.1	602004022179.1
GERMANY	04/27/2009	09075188.4	602004036335.9
GREAT BRITAIN	09/16/2004	04816875.1	1667964
GREAT BRITAIN	04/27/2009	09075188.4	2100877
GREECE	09/16/2004	04816875.1	1667964
HONG KONG	12/11/2006	06113590.1	1092784
HONG KONG	03/15/2010	10102665.8	HK1137737

WEST\242273251.5 354271-000509

Country	Filing Date	Filing number	Grant number
HUNGARY	09/16/2004	04816875.1	1667964
INDIA	09/16/2004	1513/KOLNP/2010	
INDIA	09/16/2004	956/KOLNP/06	249317
IRELAND	09/16/2004	04816875.1	1667964
SRAIL	09/16/2004	174398	
TALY	09/16/2004	04816875.1	1667964
TALY	04/27/2009	09075188.4	2100877
JAPAN	09/16/2004	527026/06	4928941
KAZAKHSTAN	09/16/2004	200600440	012241
KIRGHIZISTAN	09/16/2004	200600440	012241
KOREA (SOUTH)	09/16/2004	10-2006-7007358	1111475
LUXEMBOURG	09/16/2004	04816875.1	1667964
MEXICO	09/16/2004	PA/A/2006/003061	266596
MOLDOVA (REP)	09/16/2004	200600440	012241
MONACO	09/16/2004	04816875.1	1667964
NETHERLANDS	09/16/2004	04816875.1	1667964
NEW ZEALAND	09/16/2004	545943	545943
NORWAY	09/16/2004	20061728	
PHILIPPINES	09/16/2004	1-2006-500560	1-2006-500560
POLAND	09/16/2004	04816875.1	1667964
PORTUGAL	09/16/2004	04816875.1	1667964
ROMANIA	09/16/2004	04816875.1	1667964
RUSSIA	09/16/2004	200600440	012241
SINGAPORE	09/16/2004	200806114-5	145752
SINGAPORE	09/16/2004	200601663-8	120515
SLOVAK REPUBLIC	09/16/2004	04816875.1	1667964
SLOVENIA	09/16/2004	04816875.1	1667964
SOUTH AFRICA	09/16/2004	2006/3085	2006/3085
SPAIN	09/16/2004	04816875.1	1667964
SPAIN	04/27/2009	09075188.4	2100877
SRI LANKA	09/16/2004	14022	
***************************************			**************************************

Country	Filing Date	Filing number	Grant number
SWEDEN	09/16/2004	04816875.1	1667964
SWITZERLAND	09/16/2004	04816875.1	1667964
SWITZERLAND	04/27/2009	09075188.4	2100877
TADJIKISTAN (TAJIKISTAN)	09/16/2004	200600440	012241
TAIWAN	09/17/2004	93128361	1336238
TURKEY	09/16/2004	04816875.1	1667964
TURKMENISTAN	09/16/2004	200600440	012241
UKRAINE	09/16/2004	a200603107	87467
UNITED STATES	09/16/2004	10/942478	7301050
UNITED STATES	10/15/2007	11/872417	7635718
UNITED STATES	11/23/2009	12/623824	8106095
UNITED STATES	12/21/2011	13/332453	
VIETNAM	09/16/2004	1-2008-02871	9925
VIETNAM	09/16/2004	1-2006-00426	8495

## EXHIBIT C

## Trademarks

<u>Description</u>	Registration/ Application <u>Number</u>	Registration/ Application <u>Date</u>
CYMABAY	85954299	6/7/13
CYMABAY	85954291	6/7/13
METABOLEX	74604849	11/30/94

## EXHIBIT D

Mask Works

Description Registration/ Registration/ Application Number Application

<u>Date</u>

None.

WEST\242273251.5

**TRADEMARK REEL: 005184 FRAME: 0225** 

**RECORDED: 12/31/2013**